More On

Johnson & Johnson to pay $181 million to settle Risperdal case

36 U.S. states accused the company of improperly marketing its antipsychotic drug

Johnson & Johnson (J&J) announced yesterday that it will pay $181 million to settle claims with 36 U.S. states and the District of Columbia that it marketed its antipsychotic drugs, Risperdal and Invega, for unapproved uses.

The deal ends one chapter of a prolonged saga concerning J&J’s drug marketing practices between 1998 and 2004. According to state and federal officials, the company and its Janssen Pharmaceuticals Inc. subsidiary marketed Risperdal and Invega, designed to treat schizophrenia, as a remedy for bipolar disorder, dementia and mood and anxiety disorders. Some of these marketing efforts were allegedly targeted at the elderly, adolescents and children.

Alanna Byrne

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.